{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.11","value":"1.52"},{"groupId":"OG001","spread":"20.06","value":"-1.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"151"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.92","value":"4.17"},{"groupId":"OG001","spread":"20.29","value":"0.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.20","value":"3.58"},{"groupId":"OG001","spread":"23.71","value":"-1.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.80","value":"3.60"},{"groupId":"OG001","spread":"23.12","value":"-1.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"149"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.50","value":"3.13"},{"groupId":"OG001","spread":"22.12","value":"-1.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.55","value":"4.22"},{"groupId":"OG001","spread":"22.38","value":"-1.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"title":"Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.71","value":"3.82"},{"groupId":"OG001","spread":"20.78","value":"-1.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"134"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.28","value":"6.60"},{"groupId":"OG001","spread":"22.17","value":"-0.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"128"}],"units":"Participants"}],"title":"Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.55","value":"4.91"},{"groupId":"OG001","spread":"20.35","value":"-1.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"124"}],"units":"Participants"}],"title":"Cycle 10 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.06","value":"4.34"},{"groupId":"OG001","spread":"20.18","value":"-1.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"title":"Cycle 11 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.37","value":"8.59"},{"groupId":"OG001","spread":"22.40","value":"0.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.76","value":"7.08"},{"groupId":"OG001","spread":"20.63","value":"-1.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"title":"Cycle 13 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.62","value":"9.75"},{"groupId":"OG001","spread":"21.43","value":"-0.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Cycle 14 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.14","value":"5.26"},{"groupId":"OG001","spread":"20.51","value":"0.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"103"}],"units":"Participants"}],"title":"Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.73","value":"6.33"},{"groupId":"OG001","spread":"20.94","value":"-1.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"title":"Cycle 16 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.04","value":"7.27"},{"groupId":"OG001","spread":"22.18","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Cycle 17 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.16","value":"8.70"},{"groupId":"OG001","spread":"20.56","value":"-0.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.42","value":"12.40"},{"groupId":"OG001","spread":"20.12","value":"-1.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"title":"Cycle 19 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.97","value":"10.78"},{"groupId":"OG001","spread":"20.40","value":"-1.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"Cycle 20 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.81","value":"12.50"},{"groupId":"OG001","spread":"21.54","value":"-1.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"title":"Cycle 21 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.27","value":"17.98"},{"groupId":"OG001","spread":"21.24","value":"0.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Cycle 22 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.02","value":"15.56"},{"groupId":"OG001","spread":"20.73","value":"3.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Cycle 23 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.28","value":"14.81"},{"groupId":"OG001","spread":"14.88","value":"0.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.50","value":"15.00"},{"groupId":"OG001","spread":"17.18","value":"3.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Cycle 25 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.90","value":"-6.14"},{"groupId":"OG001","spread":"25.86","value":"-11.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a cancer-specific instrument that contains 30 items \\& provides multidimensional assessment of HRQL. EORTC QLQ-C30 includes global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale \\& are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as (\\[{Q29+Q30}/2\\]-1)/6\\*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant. Results reported for primary analysis with data cut-off date 7-Feb-2020.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received carfilzomib 20 mg/m\\^2, IV infusion on Days 1, and 2 in Cycle 1, and then escalated to 56 mg/m\\^2 on Days 8, 9, 15 and 16 of Cycle 1 and then on Days 1, 2, 8, 9, 15 and 16 of each subsequent 28-day treatment cycle along with dexamethasone 20 mg, PO or IV on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day treatment cycle until disease progression or unacceptable adverse event or participant's decision to discontinue the study treatment or any other reason, whichever comes first (maximum exposure: 114 weeks).","id":"OG000","title":"Carfilzomib + Dexamethasone (Kd)"},{"description":"Participants received isatuximab 10 mg/kg, IV infusion on Days 1, 8, 15 and 22 in Cycle 1, and then on Days 1 and Day 15 of each 28-day treatment cycle plus carfilzomib 20 mg/m\\^2, IV on Days 1, and 2 in Cycle 1, and then escalated to 56 mg/m\\^2 on Days 8, 9, 15 and 16 of Cycle 1 and then on Days 1, 2, 8, 9, 15 and 16 of each subsequent 28-day treatment cycle and dexamethasone 20 mg, PO or IV on Day 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day treatment cycle until disease progression or unacceptable adverse event or participant's decision to discontinue the study treatment or any other reason, whichever comes first (maximum exposure: 111 weeks).","id":"OG001","title":"Isatuximab + Carfilzomib + Dexamethasone (IKd)"}],"paramType":"MEAN","populationDescription":"Analysis was performed on ITT population. Here, 'Number analyzed' signifies participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)","title":"Health Related Quality of Life (HRQL): Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Specific Questionnaire With 30 Items (EORTC QLQ-C30): Global Health Status Score at Specified Timepoints","type":"SECONDARY","unitOfMeasure":"score on a scale"}